Shield Therapeutics reported a 41% increase in revenue to $30.4 million in the first half of 2026, boosted by a $7.9 million milestone payment from partner ASK and higher royalties. Despite this, group revenue and ACCRUFeR net revenue declined due to softer second-quarter trading and changes in Medicaid prescription rules affecting prices. The company shifted focus to commercial patients, growing that segment by 27%, with total prescriptions up 21%. Cash reserves fell to $8.3 million by June, and the company secured a new contract expanding clinic access. Shares fell 20.5% following the report, while the company remains on track for profitability in 2026.
Rosenblatt Securities initiated coverage of SanDisk with a Buy rating and a $2,400 price target, causing SanDisk shares to surge 6% and lifting the broader memory sector. The analyst highlighted SanDisk's advanced NAND flash memory technology as crit...
Seagate Technology's stock surged from $207 to a 52-week high of $1,144, driven by strong demand in AI infrastructure and cloud storage. Despite a recent 10% pullback, analysts remain bullish, with a consensus target around $1,125 and some forecasts ...
Micron Technology's stock fell over three months despite strong earnings and AI-driven demand for its memory chips. While the consensus target suggests a 45% upside, analyst Ben Reitzes from Melius Research projects a 110% rise, citing multi-year sup...
Seagate Technology's stock is predicted to hit $900 per share on October 27, 2026, coinciding with its fiscal Q1 2027 earnings release. The company has guided revenue around $4.10 billion and non-GAAP EPS near $7.30, following four consecutive quarte...
Seagate's stock has risen nearly 300% over the past year, fueled by strong demand for AI data storage as hyperscalers need vast capacity for their models. The company reported record revenue and cash flow, with management forecasting at least 20% ann...
